PuroClean Honors Local Leaders with PuroClean Cares® National Superhero Day Campaign
The Paramedics of Property Damage Celebrate Community Heroes Nationwide
TAMARAC, Fla., June 2, 2025 /PRNewswire/ -- PuroClean, one of the nation's leading restoration and remediation franchises, is wrapping up its PuroClean Cares National Superhero Day campaign, recognizing heroes nationwide who have made a significant impact in their community. Rooted in strong values of service and community giveback, PuroClean is overjoyed to honor unsung heroes across the country with awards, recognitions, and events to celebrate their service and dedication.
In celebration of National Superhero Day on April 28, PuroClean Franchise Owners partnered with local community groups and organizations, nominating important figures in their market who they deem superheroes. These local heroes included first responders, teachers, health care workers, volunteers, and everyday citizens who have made a difference in their community. The initiative was embraced by over a dozen PuroClean locations across the country, reinforcing the brand's commitment to service and community engagement.
"National Superhero Day is about honoring the real-life heroes who consistently, but all too often quietly, uplift their local communities," said Steve White, President and COO of PuroClean. "At PuroClean, we believe in stepping up for others, and this initiative allows our Franchise Owners to recognize those in their community who embody the same spirit. We're proud to see so many of our teams participating and shining a light on the individuals who truly make a difference."
These efforts were made possible by PuroClean Franchise Owners, their teams, and the entire PuroClean network.
Standout efforts include:
Caroline Bonnen, PuroClean in Greenlawn, NY: This Franchise Owner chose Harrison Smith from Long Island Cares to honor as their superhero for his dedication to fighting food insecurity, as well as his devoted coordination of disaster relief efforts for the underserved community.
Trey and Janice Bell, PuroClean in Elyria, OH: The Bells honored Joe Matuscak, the Chief Marketing and Development Officer of Riveon Mental Health and Recovery, for his demonstration of exceptional service and impactful contributions in the community.
Avi Sohal, PuroClean in Gilbert, PA: Avi and the PuroClean of Gilbert team showed appreciation to the local fire chief of Jackson Township Volunteer Fire Company for 15 years, Clifford Opelt. They surprised him with a backyard barbecue and a $1,000 donation to his fire company.
Gregory and Kimberly Arianoff, PuroClean of Hilo, HI: The Arianoffs honored Larry Reitzer, Board President of Hilo Education Arts Repertory, who, in addition to presenting theater, also offers theatrical training to at-risk and underserved youth in the local community. This PuroClean team coordinated a surprise lunch to honor his commitment to the Hilo community and presented him with a medal, superhero kit, and a letter of recognition.
Craig and Jenny Hawkins, PuroClean in Woodinville, WA: The Hawkins recognized Maurice Leary, a local community member with Step It Up Camp!, working with kids from all different backgrounds and helping them feel seen and prepared for life in a way that goes beyond school.
Gianni Cortes, PuroClean in New Port Richey, FL: This franchise honored Philip Meltzer, a local industrial hygienist and dedicated disaster recovery professional at Germ Masters Environmental, working closely with Gianni and his PuroClean team, keeping homes and businesses environmentally safe. They surprised him with a celebratory dinner to show their appreciation.
Charles and Sharon Atkins, PuroClean in Cleveland, TN: The Atkins chose "Big Tom" and Sabrina Anderson as their superheroes. Owners of Big Tom's Bar and Grill, this pair nearly lost everything—health, marriage, and hope—until Restaurant: Impossible helped them rise. Now, they feed thousands each holiday, expecting nothing in return.
Keegan Trudgen and Tim Lohse, PuroClean in Chicagoland, IL: This franchise recognized Paul Rocco, National Operations Director for their PuroClean locations. Paul leads the charge across multiple states, helping families and businesses rebuild after fires, floods, storms, and other life-altering events, and on the side, also a Personal Trainer, Paul often helps his team members with nutrition plans and routines for free.
Thomas Maguire, PuroClean in Spartanburg, SC: This location chose to honor local community member Beverly Benson for her dedication to helping those in need by consistently donating to local food and homeless shelters and advocating for mental health groups.
Brett Dalrymple and Dennis O'Brien, PuroClean in Warrenton and Springfield, VA: This franchise honored Master Deputy Chris Meyers, a steadfast advocate for Special Olympics in the community. He launched the Champions Together Unified Special Olympics Program at Liberty High School and is a School Resource Officer. This PuroClean team presented him with a surprise donation of $500.
Christopher Louangrath, Calvin Louangrath, and Guillermo Rocha, PuroClean in Gilberts, IL: The PuroClean of West Elgin team honored military veteran and community partner Mike Baumgartner, CEO/President of Apex Gear Service, for his tireless missionary work in Sierra Leone, Bangladesh, and the local church community.
Jessie and Jennifer Wine, PuroClean in Burlington, WI: The Wines combined the National Superhero Day campaign with the PuroClean Cares Adopt A Classroom campaign. The Burlington community nominated Ms. Rachel Hanspal, of Curtis Strange Elementary School, as the teacher who stood out among the rest, and they presented her with supplies at a school assembly to honor her. They later returned to the school to deliver a donation of $1,000 to the teacher.
Through initiatives like PuroClean Cares National Superhero Day or Season of Giving, as well as their daily remediation and restoration services, PuroClean supports homeowners and businesses in recovering from property damage while also recognizing community members across the country who embody the company's values of service and engagement.
For more information about PuroClean, call 800-351-2282, visit www.PuroCleanFranchise.com, or visit them on LinkedIn at www.linkedin.com/company/purocleanfranchise/.
About PuroClean
PuroClean is a leading, world-class service brand for property water damage remediation, fire and smoke damage restoration, mold remediation, and biohazard clean-up services, working with both residential and commercial customers across the U.S. and Canada. Founded in 2001, PuroClean is a diverse, fast-growing network of nearly 500 North American franchise locations, each independently owned and operated. With a commitment to respond within two hours, the professionals at PuroClean are thoroughly screened, insured, and trained in utilizing the latest cutting-edge mitigation technology to complete the remediation task at hand. For more information about PuroClean, call 800-775-7876 or visit www.PuroClean.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/puroclean-honors-local-leaders-with-puroclean-cares-national-superhero-day-campaign-302470886.html
SOURCE PuroClean
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Cumberland CID, One Cumberland, and the Chattahoochee River National Recreation Area Celebrate the Opening of Paces Mill After $6.3 Million Renewal
Newly restored park delivers safer access, greener infrastructure, and an expansive "front porch" on the Chattahoochee River for 270,000+ annual visitors Media Assets CUMBERLAND, Ga., June 7, 2025 /PRNewswire/ -- Hundreds of residents, elected officials, business and civic leaders, and park enthusiasts gathered this morning as the Cumberland Community Improvement District (CID), nonprofit One Cumberland, and the Chattahoochee River National Recreation Area (CRNRA) cut the ribbon on the renewed Paces Mill in the Palisades Unit of the CRNRA. The celebration marked the completion of Phase One of New Day Palisades, a two‑phase, $15.8 million project to rehabilitate 22 acres of greenspace and riverfront trails along the Chattahoochee River. "When we launched the New Day Palisades project, we envisioned more than just fresh pavement – we imagined a front porch on the Chattahoochee in the national park that belongs to everyone," said Bob Voyles, board chair of the Cumberland CID. "Today, that vision springs to life. The redesigned circulation system, resilient native landscapes, and direct river touchpoints mean every school bus, wheelchair, kayak trailer, and pair of hiking boots can arrive safely, move easily, and experience the river up close. This milestone reflects years of collaboration among the Cumberland CID, the National Park Service, our federal delegation, commercial property owners, and thousands of residents who asked us to re‑imagine their backyard national park." Phase One Highlights A newly engineered parking hub and bus‑drop loop untangle traffic and separate pedestrians from vehicles, creating a welcoming destination for more than 270,000 annual visitors. Space for a sweeping native meadow, bioswales and precision grading now capture and filter stormwater before it reaches the river, stabilizing soils and enhancing ecological resilience across the 22‑acre site. Rebuilt boardwalks, gently graded paths guide every visitor – regardless of ability – directly to the water's edge within minutes, turning the Chattahoochee into an immersive classroom and playground. The $6.3 million phase one was funded with $4.3 million provided by the Cumberland CID and $2 million in federal appropriations championed by Georgia's congressional delegation, including U.S. Senators Jon Ossoff and Raphael Warnock, and U.S. Representatives Barry Loudermilk, Lucy McBath, and David Scott. "Today's ribbon cutting is a celebration of partnerships and a representation of what is possible when federal, state, and local leaders work together in service to our community," said U.S. Representative Lucy McBath (GA-06). "The reopening of Paces Mill shows how smart investments in public land improve our health, strengthen our economy, and preserve Georgia's natural treasures for generations to come. As your Congresswoman, I was proud to help secure federal funding for Phase One of this project, and I look forward to remaining engaged as we look ahead to the next stage of development for this wonderful community asset." "The completion of Phase One marks an exciting time in the effort to revitalize Paces Mill, so the hundreds of thousands of visitors each year can continue to enjoy this area for decades to come," said Congressman Barry Loudermilk (GA-11). "I'm especially proud of the hard work Cumberland Community Improvement District and the nonprofit One Cumberland have done to make this vision a reality, and for the funds Congress was able to appropriate to help complete Phase One." "The New Day Palisades project is more than a transformation – it's a strategic investment in Cumberland's ecological assets," said Rob Garcia, board chair of One Cumberland. "Through careful planning, we are ensuring Paces Mill remains a cherished destination for outdoor recreation while strengthening our community's identity with improved accessibility, cultural enrichment, and environmental stewardship. We look forward to engaging the community to help move forward the vision of Phase Two." As funding allows, the $9.5 million Phase Two will begin in 2026 with an expected completion in spring 2027. One Cumberland will work to help raise funds for Phase Two. Phase Two will feature a new Visitor Information Center with enhanced restrooms and changing facilities, an open-air pavilion, and additional elements that will provide greater access to the Chattahoochee River. Looking ahead: Phase Two (2026‑2027)Planning is already underway for a $9.5 million second phase that will crown Paces Mill with: A fully ADA‑accessible Visitor Information Center featuring modern restrooms and changing rooms. An open‑air pavilion for environmental education and community events. Broad river steps beneath the U.S. 41 bridge and additional habitat and trail enhancements. River overlooks to increase accessibility to the Chattahoochee River. When complete in spring of 2027 – timed to coincide with the CRNRA's 50th anniversary, established in 1978 when President Jimmy Carter signed the enabling legislation – the two‑phase effort will stand as the single largest investment in public access to the Chattahoochee within the national park. To learn more about the New Day Palisades project, please visit About Cumberland CIDThe Cumberland Community Improvement District (CID), Georgia's first CID, is one of the nation's premier models of public-private collaboration. More than 190 Commercial property owners pay additional property taxes, and the CID leverages these funds to advance key projects for increased access, better connectivity, and a more vibrant character throughout the Cumberland area. Each year, the CID creates more value for the community by initiating and leading enhancements to make Cumberland a more attractive place to operate a business, to work, and to live. Today, Cumberland has a $26.6 billion annual impact on Georgia's economy. Cumberland is home to leading companies including The Home Depot, Papa Johns, TKE, Comcast, Genuine Parts Company, and more. To learn more about the Cumberland CID, the Cumberland Sweep, and the Cumberland Hopper autonomous shuttle pilot program, please visit About One CumberlandOne Cumberland is committed to ensuring Cumberland's national parkland receives sustainable investment, care, and recognition. Established in 2022 by the Cumberland CID, the nonprofit aims to create a greater sense of ownership, affiliation, and connectivity between Cumberland and the community. One Cumberland's mission is to protect and conserve the natural resources of Cumberland and establish the district as a vibrant, diverse community through the enrichment of cultural amenities, quality of life, improved access, and environmental stewardship. For more information visit View original content to download multimedia: SOURCE Cumberland Community Improvement District Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
Nucleus Genomics Launches Nucleus Embryo, Genetic Optimization Software Alongside Partnership with Genomic Prediction
Parents pursuing IVF now have a new level of choice to empower their family planning NEW YORK, June 4, 2025 /PRNewswire/ -- With U.S. birthrates plummeting and IVF on the rise, Nucleus Genomics today launched Nucleus Embryo, the first genetic optimization software that lets parents see and understand a complete genetic profile to select an embryo. "Before there's a heartbeat, there's DNA," said Kian Sadeghi, founder and CEO of Nucleus. "One file containing DNA and genetic markers can tell you more about your baby's future than any other test a doctor could possibly run at this stage. Most clinics stop at whether an embryo will develop. For many parents, that's not enough. Patients have long asked for more transparency from clinics, and Nucleus Embryo is an important step toward complete data ownership for parents planning their families." The software enables parents to analyze and compare up to 20 embryos across over 900 hereditary conditions and 40 additional analyses beyond basic viability, spanning cancers, chronic conditions, appearance, cognitive ability, mental health, and more. To widen access to the software, Nucleus will partner with Genomic Prediction, the first company to offer genome-wide screening on embryos. The partnership sets a new standard in genetic medicine, continuing Genomic Prediction's decade-long history of giving hopeful parents the best possible chance of implanting healthy embryos. The company's analyses focus on hereditary conditions, acting as the first line of defense against chronic and rare diseases. "As an organization, we are committed to supporting patients' rights to their DNA and any information that can aid in their family-building journey," said Kelly Ketterson, CEO of Genomic Prediction. "We have a legacy of innovation aimed at providing patients with access to the best scientific resources. Our partnership with Nucleus opens access to information our patients have requested and allows us to uphold our commitment to this legacy." Nucleus' partnership with Genomic Prediction reflects a growing shift in how parents think about genetics as a tool to give children the best possible start in life. A wide-ranging study of Americans found the majority accepted the use of genetic technology to choose embryos based on health and personality traits. Four in 10 parents would use genetic optimization as another tool to understand their future child's cognitive abilities. Most women undergo three to six IVF cycles before successfully having a baby, with each cycle costing up to $25,000. Many embryos are unviable within days of being fertilized, leaving parents with few to choose from. Facing high stakes, clinicians often recommend genetic testing to optimize a couple's chances of a healthy pregnancy. But these tests typically stop at a select number of hereditary conditions and chromosome count. Now, advanced genetic analysis from Nucleus gives parents a new window into the health and well-being of their future child. Nucleus Embryo provides a comprehensive genetic profile for each embryo, encompassing hereditary genetic diseases, like cystic fibrosis and hemochromatosis, alongside genetic measures of cognitive ability, mental health, and risk for chronic diseases. Wide access to genetic insights for embryos can also help extend lifespan from the earliest stages of life. While more than half of all deaths annually in the U.S. are attributed to chronic, age-related conditions — such as Alzheimer's disease, diabetes, cancer, and heart disease — research shows embryonic selection can materially help reduce disease risk for these conditions. "We celebrate health optimization and the pursuit of longevity in every other part of life via our focus on training, supplements, and sleep," Sadeghi said. "We all know health isn't just the absence of disease. It's the ability to understand our bodies and genetic makeup to reach our full potential. Now we can apply this principle to life's inception." About Nucleus Genomics Nucleus builds software for generational health. Inspired by the loss of his cousin who died of a rare — yet preventable — genetic disease, Nucleus founder and Thiel Fellow Kian Sadeghi left an Ivy League university to build a product that could have saved her life. Our advanced DNA health test and analysis takes the guesswork out of your health, whether it's perfecting your protocols, knowing your risk for cancer, or planning for a healthy family. Follow us on social media @nucleusgenomics. About Genomic Prediction Genomic Prediction, Inc. is the frontrunner in advanced embryo screening. Our proprietary LifeView platform is state-of-the-art technology that assesses embryos for genetic health aimed at improved IVF outcomes. The LifeView Embryo Health Score Test (EHS) offers insight into the likelihood of developing conditions driven by multiple genes. It tests for significant health issues, including cardiovascular disease, diabetes mellitus, certain cancers, and mental health conditions. The EHS results are derived from the same embryo sample used in the following PGT tests: PGT-A: Identifies chromosome abnormalities in embryos. PGT-A+: Pinpoints the origin (paternal, maternal, or embryonic) of chromosome abnormalities. PGT-M: Decreases the chances of passing on monogenic (single-gene) conditions. PGT-SR: Detects chromosome abnormalities and structural imbalances, providing clarity between normal and balanced chromosomes. View original content to download multimedia: SOURCE Nucleus
Yahoo
2 days ago
- Yahoo
The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC
CHENGDU, China, June 6, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", today announced that results from its registrational study (OptiTROP-Lung03) evaluating sacituzumab tirumotecan (sac-TMT) versus docetaxel in patients with previously treated advanced EGFR-mutant non-small cell lung cancer (NSCLC) have been published in The British Medical Journal (impact factor: 93.6). These data were also presented as an oral presentation in the Lung Cancer—Non–Small Cell Metastatic session (Abstract #8507) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Based on the encouraging data from this study, sac-TMT was approved for marketing by the National Medical Products Administration (NMPA) for the treatment of adult patients with epidermal growth factor receptor (EGFR) mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy in March 2025. This marks the first global approval of a TROP2 ADC for a lung cancer indication. The published results are based on OptiTROP-Lung03, an open-label, randomized, multicenter registrational study evaluating the efficacy and safety profile of sac-TMT monotherapy versus docetaxel for the treatment of patients with locally advanced or metastatic EGFR-mutant NSCLC who have failed after treatment with an EGFR-TKI and platinum-based chemotherapy. A total of 137 patients with advanced EGFR-mutant NSCLC who had progressed after EGFR-TKI and platinum-based chemotherapy were randomized (2:1) to receive sac-TMT (5 mg/kg once every 2 weeks) or docetaxel (75 mg/m2 once every 3 weeks) until disease progression, intolerable toxicity or other reason for discontinuation, with a median follow-up time of 12.2 months (Data cutoff date: December 31, 2024). Sac-TMT achieved statistically significant and clinically meaningful outcomes compared to docetaxel: Confirmed objective response rate (ORR) (As assessed by blinded independent review committee (BIRC): 45% (95% CI, 35-56) vs 16% (95% CI, 7-30). Median progression-free survival (PFS) (As assessed by BIRC: 6.9 months [sac-TMT; 95% CI, 5.4-8.2] vs 2.8 months [docetaxel; 95% CI, 1.6-4.1], hazard ratio (HR)= 0.30 [range, 0.20 -0.46], one-sided p<0.0001; as assessed by investigator (INV): 7.9 months [sac-TMT; 95% CI, 6.2-9.5] vs 2.8 months [docetaxel; 95% CI, 1.5-3.8], HR=0.23 [95% CI, 0.15-0.36], one-sided p<0.0001). With 36.4% of patients in docetaxel group crossing over to receive sac-TMT, median overall survival (OS) was not reached (NR) for both groups (HR=0.49; 95% CI, 0.27-0.88; one-sided p=0.007). The median OS analysed by pre-specified rank-preserving structural failure time (RPSFT) model adjusted for crossover was 9.3 months for docetaxel and NR for sac-TMT (HR=0.36; 95% CI, 0.20-0.66). Efficacy benefit favored patients with sac-TMT over docetaxel across all pre-specified subgroups, including prior EGFR-TKI therapy, brain metastases, EGFR mutation type, etc. Grade ≥ 3 treatment-related adverse events (TRAEs) occurred in 56.0% of patients in sac-TMT group vs 71.7% in docetaxel group. The results demonstrated that sac-TMT monotherapy achieved statistically significant and clinically meaningful improvements in objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) compared to docetaxel, with a manageable safety profile. Sac-TMT is being extensively studied in the NSCLC field. Covering treatment settings from later-line therapy to early-stage postoperative adjuvant therapy, including both monotherapy and combination regimens. Currently, five company-led registrational clinical studies for sac-TMT in NSCLC are underway in China. Meanwhile, Merck Sharp & Dohme（the tradename of Merck & Co., Inc., Rahway, NJ, USA）is also conducting five global Phase III clinical trials of sac-TMT for NSCLC in regions where it has exclusive rights. Professor Li Zhang, National Lead Principal Investigator, Medical Oncologist and Deputy Director of the Lung Cancer Research Centre at Sun Yat-Sen University, stated: "EGFR mutation is the most common driver alteration in NSCLC. The prevalence of EGFR mutations reaches 28.2% among NSCLC patients in China. Although third-generation EGFR-TKIs have become the standard of care for advanced EGFR-mutant NSCLC and may significantly improve PFS, acquired resistance remains inevitable. Combining EGFR-TKIs with chemotherapy can offer additional survival benefits to some patients, but this approach is limited by safety concerns and may compromise future treatment options, posing significant clinical challenges. The publication of the OptiTROP-Lung03 study in the British Medical Journal marks a major milestone—not only highlighting international recognition of this study outcomes in lung cancer, but also demonstrating the global competitiveness of sac-TMT as a novel TROP2 ADC." Dr. Michael Ge, CEO of Kelun-Biotech, commented: "We are thrilled to see the OptiTROP-Lung03 study published in a top-tier journal. Currently, EGFR-TKIs and chemotherapy remain the standard of care for patients with EGFR-mutant advanced NSCLC, but the challenge of increasing efficacy with manageable tolerability. The results from OptiTROP-Lung03 highlight significant survival benefits with manageable safety profile and suggest that sac-TMT could emerge as a new standard of care for this population. We remain committed to working with our partners to establish sac-TMT as a new standard of care for this patient population and improve outcomes for lung cancer patients worldwide." Registrational Study Led by Kelun-Biotech OptiTROP-Lung03: Sac-TMT monotherapy versus docetaxel for locally advanced or metastatic EGFR-mutant NSCLC after treatment failure with EGFR-TKI and platinum-containing chemotherapy； OptiTROP-Lung04: Sac-TMT monotherapy versus pemetrexed in combination with platinum for locally advanced or metastatic non-squamous NSCLC with EGFR mutations that have failed EGFR-TKI therapy； OptiTROP-Lung05: Sac-TMT combined with pembrolizumab versus chemotherapy combined with pembrolizumab for first-line treatment of PD-L1-positive locally advanced or metastatic NSCLC; OptiTROP-Lung06: Sac-TMT combined with pembrolizumab versus chemotherapy combined with pembrolizumab for the first-line treatment of PD-L1-negative locally advanced or metastatic non-squamous NSCLC; OptiTROP-Lung07: First-line treatment of locally advanced or metastatic NSCLC with EGFR mutations by sac-TMT in combination with ositinib. Registrational Study Led by MSD NSCLC not achieving a pCR after neoadjuvant therapy followed by surgery. NSCLC expressing PD-L1 >50% pre-treated NSCLC with EGFR mutations or other genomic alterations EGFR-mutated, advanced non-squ NSCLC progressed on prior EGFR-TK metastatic sg NSCLC About sac-TMT Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, BC, gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells. In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macao, and Taiwan). To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) based on the OptiTROP-Breast01 study and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy based on the OptiTROP-Lung03 study. Sac-TMT became the first domestic ADC with global intellectual property rights to be fully approved for marketing. It is also the world's first TROP2 ADC to be approved for marketing in a lung cancer indication. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the National Medical Products Administration (NMPA), and were reviewed via the priority review and approval process. As of today, the Company has initiated 8 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other agents for several types of cancer. These studies are sponsored and led by MSD. About Kelun-Biotech Kelun-Biotech（ a holding subsidiary of Kelun Pharmaceutical ( which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel coupled drug products in clinical or preclinical research stage. For more information, please visit Media: klbio_pr@ View original content to download multimedia: SOURCE Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
